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Abstract
Background: Antibodies produced in response to infection with any of the four serotypes of dengue virus
generally provide homotypic immunity. However, prior infection or circulating maternal antibodies can also
mediate a non-protective antibody response that can enhance the course of disease in a subsequent heterotypic
infection. Naturally occurring human monoclonal antibodies can help us understand the protective and pathogenic
roles of the humoral immune system in dengue virus infection.
Results: Epstein-Barr Virus (EBV) transformation of B cells isolated from the peripheral blood of a human subject
with previous dengue infection was performed. B cell cultures were screened by ELISA for antibodies to dengue
(DENV) envelope (E) protein. ELISA positive cultures were cloned by limiting dilution. Three IgG1 human
monoclonal antibodies (HMAbs) were purified and their binding specificity to E protein was verified by ELISA and
biolayer interferometry. Neutralization and enhancement assays were conducted in epithelial and macrophage-like
cell lines, respectively. All three HMAbs bound to E from at least two of the four DENV serotypes, one of the
HMAbs was neutralizing, and all were able to enhance DENV infection.
Conclusions: HMAbs against DENV can be successfully generated by EBV transformation of B cells from patients at
least two years after naturally acquired DENV infections. These antibodies show different patterns of cross-reactivity,
neutralizing, and enhancement activity.
Background
Dengue viruses (DENV), members of the genus Flavi-
virus, are the most common cause of mosquito-borne
viral diseases in tropical and subtropical regions around
the world. Approximately 50 to 100 million people per
year are infected with DENV [1]. DENV infections may
be asymptomatic, but most often manifest as dengue
fever (DF), a self-limited disease. Dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS) are
more severe, life-threatening manifestations of dengue
infection. The pathogenesis of DHF/DSS is not comple-
tely understood. There are four serotypes of dengue
virus (DENV-1, DENV-2, DENV-3, and DENV-4). Infec-
tion with one serotype confers lifelong homotypic
immunity, but only short term (approximately three to
six months) cross protection against heterotypic sero-
types [2]. The risk of severe disease is greatest during
secondary, heterotypic infections in areas with more
than one circulating serotype [3]. There is evidence that
prior infection with one type can produce an antibody
response that can intensify or enhance the course of dis-
ease during a subsequent infection with a different sero-
type [1,4,5]. The possibility that vaccine components
could elicit enhancing antibody responses, as opposed to
protective responses, hasb e e nam a j o rc o n c e r ni n
designing and testing vaccines to protect against dengue
infections [6].
The DENV surface contains two proteins: a mem-
brane protein (M) and the envelope glycoprotein (E). E
proteins are glycosylated and arranged in homodimers
on the viral surface and are involved in receptor binding
and entry into susceptible cells [7,8]. The E protein is
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and thus the focus of vaccine design. This surface glyco-
protein is made up of three domains. The central
domain I is flanked on one side by domain II which
contains the hydrophobic fusion loop. This loop lies in a
pocket between the opposing E protein dimer units and
is involved in acid-catalyzed fusion [9]. After virions
gain access to an endosome, the lowered pH causes the
hinge region of domain I to flex, changing the E protein
dimer into a trimer and exposing the fusion loops on
domain II. This conformational change at low pH trig-
gers fusion of the viral and cellular endosomic mem-
branes, allowing for nucleocapsid entry into the
cytoplasm. Murine monoclonal antibodies (MMAbs) tar-
geting domain I epitopes tend to be non-neutralizing.
While there is evidence that some MMAbs binding to
domain II epitopes may be neutralizing, others are not
[7,10,11]. Domain III, on the opposite side of domain I,
contains an immunoglobulin-like structure that is
involved in host cell binding [10]. It is also thought to
be a major site for serotype-specific antibody-mediated
neutralization in mouse models [11-13].
In order to make a safe vaccine, a better understand-
ing of human humoral immune responses to natural
DENV infection is required. Although most neutralizing
antibodies are directed against the viral envelope protein
(E), the precise epitopes that elicit homotypic and het-
erotypic neutralizing antibodies in naturally infected
human subjects have not been characterized and the
relationship between neutralizing and enhancing antibo-
dies has not been defined. Studies with monoclonal anti-
bodies provide one approach to identification and
characterization of neutralization epitopes. However, to
date most anti-dengue monoclonal antibodies are of
mouse origin and have been generated from mice
immunized with E proteins or live virus [10,14]. The
extent to which the human antibody responses elicited
by DENV infections target the same or different epi-
topes is incompletely understood. The purpose of this
study was to derive human B cell lines producing
human monoclonal antibodies (HMAb) against dengue
virus E proteins in order to determine functional prop-
erties of antibodies made in response to natural infec-
tion in hosts that are actually susceptible to
complications of dengue infections. Here we present
data demonstrating that it is feasible to isolate dengue
virus E protein-specific human B cell lines more than
two years after infection.
Materials and methods
Viruses and Cells
DENV-1 strain HI-1, DENV-2 strain NG-2, DENV-3
strain H-78, and DENV-4 strain H-42, were obtained
from R. Tesh at the World Health Organization
Arbovirus Reference Laboratory at the University of
Texas at Galveston. Viruses were propagated in the
Macaca mulatta kidney epithelial cell line, LLC-MK-2,
obtained from the ATCC (Manassas, VA). LLC-MK-2
cells were grown in Dulbecco’s modified eagle medium
(DMEM) containing 10% (v/v) fetal bovine serum (FBS)
2 mM Glutamax, 100 U/ml penicillin G, 100 μg/ml
streptomycin and 0.25 μg/ml amphotericin B, at 37°C
with 5% (v/v) CO2. The cells were inoculated with den-
gue virus stock at 70% to 80% confluency, cultured in
DMEM and 10% FBS for seven days, at which time
medium was changed to Protein Free Hybridoma Med-
ium (Gibco, Carlsbad, CA). After ten days in culture,
supernatant fluids were collected and treated with 1%
Triton-X 100 to solubilize and inactivate virus. Adherent
cells were collected by treatment with trypsin-EDTA for
three minutes. Cells were then pelleted by centrifugation
at 1000 rpm for 10 minutes. The pellet was re-sus-
pended in 5 ml of PBS containing 1% Triton-X 100.
The detergent treated preparations were then mixed
thoroughly and aliquoted and frozen at -20°C for later
use. K-562 hematopoietic cells (ATCC, Manassas VA),
used for virus enhancement assays, were grown in
RPMI-1640, 10% (v/v) FBS, 2 mM Glutamax, 100 U/ml
penicillin G, 100 μg/ml streptomycin and 0.25 μg/ml
amphotericin B, at 37°C with 5% (v/v) CO2.
Patient Sample
A patient was identified who had been hospitalized in
Singapore with a dengue virus infection in April of
2005. The infection was likely acquired while the patient
was traveling in Myanmar. Blood was drawn in Septem-
ber 2007, after informed consent was obtained, and per-
ipheral blood mononuclear cells (PBMCs) were isolated
by Ficoll-Hypaque gradient centrifugation and viably
frozen in liquid nitrogen. The patient’s serum was tested
by ELISA and neutralization assays in an attempt to
determine the likely infecting serotype. Institutional
Review Board approval was obtained for this study at all
participating institutions.
Epstein-Barr Virus Transformation
The production of HMAbs by EBV-transformation of B
cells has been described elsewhere [15-17]. Briefly, viably
cryopreserved PBMCs were thawed, washed in Hank’s
Buffered Salt Solution, and inoculated with EBV (B95-8
strain). Cells were suspended in RPMI containing 20%
FBS, Primacin® (InVivoGen, San Diego, CA)a n d2g / m l
CpG 2006 (Midland Certified Reagent Co., Midland,
TX) and plated at 10
4 cells per well in 96 well tissue
culture plates previously seeded with approximately
50,000 irradiated mature macrophages per well derived
from PBMC of healthy blood donors which served as
“feeder cultures” that promote outgrowth of transformed
B cells. Antibody-positive wells that contained growing
cells were sub-cultured at several dilutions and re-
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and produce antibody during several low cell density
passages were finally cloned at limiting dilution. Defini-
tively cloned cell lines were expanded to grow as sus-
pension cultures in stationary 490 cm
2 roller bottle
cultures (Corning, Corning, NY) from which cell culture
fluid was harvested weekly. HMAbs were purified from
one to two liters of culture supernatant by Protein A
affinity chromatography. The IgG subclass and light
chain type of each antibody was determined by reactivity
with MMAbs to the four heavy chain subclasses (South-
ern Biotech, Birmingham, AL) and polyclonal goat anti-
bodies to kappa and lambda chains by ELISA using
established methods.
ELISA to Detect Human and Murine Anti-Dengue Virus
Monoclonal Antibodies
Transformed B cell cultures were screened for antibody
production using a modification of an immunoassay
described previously in which virus envelope glycopro-
teins are immobilized in wells coated with Concanavalin
A (ConA) a plant lectin that binds carbohydrate moi-
eties on glycoproteins of a variety of enveloped viruses
[16]. 96-well plates (Costar®, Corning, Corning, NY) were
coated with ConA (Vector Laboratories, Burlingame,
CA) at 25 ug/ml in 0.01 M HEPES (Gibco, Carlsbad,
CA) and 100 l per well for one hour. The wells were
washed and solubilized DENV was incubated for one
hour. A requirement of this assay is that virus must be
grown in serum free medium so that viral glycoproteins
can be captured in ConA coated wells. Media containing
FBS has glycoproteins that will bind to ConA and block
capture of DENV E protein resulting in low OD read-
ings. After a wash step with PBS containing 0.1% (v/v)
Triton-X 100, un-reacted ConA binding sites in the
wells were blocked with RPMI Medium 1640 and 10%
FBS for 30 minutes. Culture fluids from each 96 well
culture plate containing EBV transformed B cells were
transferred to corresponding wells of assay plates coated
with dengue E proteins and incubated for one hour at
room temperature. Undiluted supernatant of murine
MAb 3H5 (ATCC HB-46), which binds to DENV-2, was
used as a positive control during the screening process
[18]. Negative controls consisted of LLC-MK-2 culture
fluid grown in parallel with no virus as well as vaccinia
expressed HIV envelope glycoprotein’sf r o mt h eA D A
strain of HIV-1 produced in serum free medium. The
wells were again washed and then incubated with 100 ul
of peroxidase-conjugated goat anti-human IgG-gamma
(Zymed, San Francisco, CA) or peroxidase-conjugated
affinity purified anti-mouse IgG (Rockland, Gilbertsville,
PA) diluted 1:2000 in PBS-0.5% (v/v) Tween 10% (w/v)
whey (BiPro, Le Sueur, MN) and 10% (v/v) FBS for one
hour. After a final wash step, color was developed with
100 μl/well tetramethylbenzidine-peroxide (TMB)-H2O2
as substrate for peroxidase. The reaction was stopped
after 4 minutes by adding 1% phosphoric acid and color
was read as optical density (OD) at 450 nm. All steps in
this ELISA were performed at room temperature.
Biolayer Interferometry Binding Assays
Real time binding assays between purified antibodies
a n dp u r i f i e dD E N VEp r o t e i n sw e r ep e r f o r m e du s i n g
biolayer interferometry with an Octet QK system (Forte-
bio, Menlo Park, CA). This system measures light inter-
ference on the surface of a fiber optic sensor, which is
directly proportional to the thickness of molecules
bound to the surface. Targets of interest are chemically
tethered to the surface of the sensor using biotin-strep-
tavidin interactions. Binding of a partner molecule to
the tethered target results in thickening of the surface,
which is monitored in real time. Purified, recombinant,
80% truncated DENV 1-4 E proteins were obtained
from Hawaii Biotechnology (Aiea, HI) [19,20]. E proteins
were biotinylated for 30 minutes at room temperature
using a 5:1 molar ratio of NHS-LC-LC-Biotin (Pierce/
ThermoFisher, Rockford, IL) and dialyzed against PBS to
remove unreacted biotinylation reagent. Biotinylated E
proteins were coupled to kinetics grade streptavidin
high binding biosensors (Fortebio, Menlo Park, CA)a t
several different concentrations. E protein binding con-
centrations that gave a signal between 0.8 and 1.2 nm
binding to the sensor surfaces within 200 seconds were
used for antibody binding studies. Unbound E proteins
were removed from the surface of the sensors by incu-
bation in PBS. Probes coupled to E protein were allowed
to bind to antibodies at several different concentrations,
and binding kinetics were calculated using the Octet
QK software package, which fit the observed binding
curves to a 1:1 binding model to calculate the associa-
tion rate constants. Antibodies were allowed to dissoci-
ate by incubation of the sensors in PBS. Dissociation
kinetics were calculated using the Octet QK software
package, which fit the observed dissociation curves to a
1:1 model to calculate the dissociation rate constants.
Association and dissociation rate constants were calcu-
lated using at least two different concentrations of anti-
body. Equilibrium dissociation constants were calculated
as the kinetic dissociation rate constant divided by the
kinetic association rate constant.
Antibody Cross-competition assay
To determine whether HMAbs recognized overlapping
or non-overlapping sites, we tested the MAbs for cross-
competition with each other and with MMAb 4G2
using an adaptation of our previously described method
[21,22]. Detergent solubilized dengue E protein in serum
free culture fluid was immobilized in Con A coated
wells at room temperature. The plates were washed and
blocked for 30 minutes at room temperature. Purified
HMAbs, MAb 4G2 or dilution buffer was incubated in
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lated HMAbs were then added to the wells at dilutions
that gave less than maximal binding and incubated for
one hour at room temperature. Bound biotinylated
HMAb was detected with horseradish peroxidase strep-
tavidin (Vector, Burlingame, CA). After the wells were
washed, the ELISA was completed as described above.
Focus-forming-unit Reduction Neutralization Titer
LLC-MK-2 target cells were seeded at a density of
approximately 500,000 cells in each well of a 12-well
plate 24 h prior to virus inoculation. Approximately 100
focus forming units (ffu) of virus were incubated with
heat inactivated patient serum or purified HMAb in
serum-free DMEM for one hour at room temperature.
Virus mixtures were allowed to infect confluent target
cell monolayers for one hour at 37°C, with rocking
every 15 minutes, after which time the inoculum was
aspirated and overlaid with fresh MEM/10% (v/v) FBS
containing 1.2% (w/v) microcrystaline cellulose (Avicel,
FMC, Newark, DE). Infected cells were then incubated
at 37°C with 5% CO2 for two days (DENV-4), three days
(DENV-1 and -3), or four days (DENV-2). Infected cul-
tures were fixed with 10% (w/v) formalin overnight at 4°
C, permeabilized with 70% (v/v) ethanol for 20 minutes,
and rinsed with PBS prior to immunostaining. Virus foci
were detected using specific mouse anti-DENV E pro-
tein MAb E60 (obtained from M. Diamond at Washing-
ton University), followed by horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin (Pierce,
Rockford, IL), and developed using AEC chromogen sub-
strate (Dako, Carpinteria, CA). Results are expressed as
pooled data from two independent experiments with
three replicates each.
Enhancement Assay
Enhancement assays were conducted using DENV-1 in
K-562 hematopoietic cells. Varying concentrations of
each HMAb were incubated with 7,500 ffu of virus for 1
hour at 37°C in 200 μl of serum free RPMI-1640, then
added to 75,000 cells in 300 μl of complete medium in a
24-well plate and incubated at 37°C with 5% CO2 for 3
days. RNA was extracted from cell lysates using the
RNeasy Mini kit (Qiagen, Valencia CA). Quantitative RT-
PCR was performed with a DENV-1 specific primer pair
(D1S and D1C) that produces a 490 bp product from the
NS1 region, using a LightCycler 480 II (Roche, Indiana-
polis, IN) and a one step LightCycler RNA Master SYBR
Green I kit (Roche) [23]. Amplification conditions were
61°C for 30 min, 95°C for 30 sec, and 45 cycles of 95°C
for 5 sec, 61°C for 20 sec, and 72°C for 30 sec.
Results
ELISA to Screen for IgG Antibody Production
We first determined that DENV E proteins captured in
assay wells coated with ConA and still retained
antigenicity. The ELISA data presented in Figure 1
shows that antibodies in a dengue positive serum
reacted strongly with ConA immobilized E proteins of
all four serotypes while a dengue negative human serum
showed only low levels of background reactivity (Figure
1). Equivalent low background reactivity (O.D. <0.300)
was also seen when the dengue positive and negative
sera were tested in ConA coated wells incubated with
tissue culture fluid lacking dengue E proteins. As further
controls, we also tested two murine MAbs with known
binding to dengue E proteins, 3H5 and 4G2 (ATCC
HB-46 and HB-112, respectively), for reactivity in this
assay. 3H5 is quite strain restricted to DENV-2 while
4G2 cross-reacts with all dengue serotypes and other
flaviviruses as well. In the Con A assay these MAbs
reacted as expected: 4G2 bound the four serotypes and
3H5 bound only to Dengue 2. [18].
Isolation of B Cell Lines Producing DENV Specific HMAbs
We identified a patient with a history of DENV infection
approximately two years previously. Serum from this
patient contained IgG antibodies that cross-reacted with
E proteins of all four strains of DENV by ELISA (Figure
1). B cells were transformed and screened for IgG anti-
bodies binding to DENV-2 E proteins immobilized in
ConA coated wells of assay plates. IgG antibodies react-
ing with DENV-2 E protein were detected in 11 of 558
(2%) of the EBV transformed B cell cultures from the
patient sample. From three of the initially positive cul-
tures we established cloned B cell lines that stably pro-
duced three MAbs, designated 2.3D, 3.6D and 4.8A. The
IgG subclass and light chain type of each antibody was
d e t e r m i n e d .B o t h3 . 6 Da n d4 . 8 Aw e r eI g G 1w i t hk a p p a
light chains while 2.3D was IgG1 with lambda light
chains.
Next we titered the binding activities of protein A
purified HMAbs with ConA-immobilized E proteins
from each DENV serotype (Figure 2). MMAbs 3H5 and
4G2 served as positive controls. Each MAb bound to E
proteins in a dose dependent fashion (Figure 2). There
was no reactivity with negative controls consisting of
LLC-MK-2 culture fluid grown in parallel with no virus
(data not shown). The patterns of cross-reactivity dif-
fered for the HMAbs; HMAb 2.3D bound strongly to
DENV-1, -2, moderately to DENV-3. Reactivity of 2.3D
with DENV-4 was observed only at high concentrations
(10 μg/ml) but binding activity dropped off rapidly with
antibody dilution. HMAb 3.6D bound strongly to
DENV-1 and -2, but binding to DENV-3 and -4 only
occurred at high concentrations (≥2 μg/ml). HMAb
4.8A bound strongly to DENV-1, -2, and -3, and moder-
ately well to DENV-4. As expected, the control mouse
M M A b3 H 5b o u n do n l yt oD E N V - 2w h i l et h eh i g h l y
cross-reactive MMAb 4G2, bound to all four serotypes
(Figures 1, 2D and 2E).
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A cross-competition assay was performed to determine
whether the three HMAbs recognized overlapping or
non-overlapping sties on DENV-1 E protein. We tested
the ability of each HMAb to block binding of each bio-
tin labeled HMAb. As shown in Figure 3, each HMAb
was able to block itself (e.g. 4.8A blocked binding of
biotin 4.8A) but was unable to block the other two
HMAbs. These results indicate that the three HMAbs
recognize non-overlapping sites on DENV E proteins. In
addition preliminary results indicated that MMAb 4G2
did not block binding of any of the HMAbs. Taken
together our results demonstrate the three human
MAbs recognize distinct non-overlapping sites, which
are also independent of the 4G2 epitope.
Neutralization
To determine which serotype was likely to have infected
the patient we performed serum neutralization assays
against each of the four strains of DENV (Figure 4). The
patient serum showed little or no neutralization activity
against either DENV-2 or DENV-4. The highest level of
neutralization activity was seen against DENV-1, sug-
gesting that this may have been the original infecting
serotype. In support of this, published data from Myan-
mar suggests that beginning in 2001, DENV-1 was the
predominant circulating strain [24]. The serum also
showed considerable neutralization activity against
DENV-3, however since the patient described only a sin-
gle dengue-like illness event, the ability of the patient’s
serum to neutralize DENV-1 and DENV-3 most likely
reflects the development of cross-reactive neutralizing
antibodies rather than exposure to a second serotype.
Because no tests were initially performed to determine
the infecting serotype, it is impossible to know for cer-
tain which one it was.
We tested the neutralizing activity of the three HMAbs
against representative strains of all four DENV serotypes
(Figure 5). Neither the 2.3D nor 3.6D antibodies showed
neutralizing activity against any DENV serotype at any
concentration tested. In contrast, the 4.8A antibody was
showed potent neutralizing activity against both DENV-1
and -3, with fifty percent neutralization at approximately 3
g/ml. Although HMAb 4.8A also showed some weak inhi-
bitory activity against DENV strains 2 and 4, the level of
inhibition did not reach 50% neutralization activity and
thus did not meet the criteria for neutralizing activity.
Enhancement
Both human polyclonal serum and mouse monoclonal
antibodies have been shown to enhance dengue virus
infections in Fc receptor bearing cells that otherwise
exhibit low susceptibility to DENV infection [25-27]. To
determine if the HMAbs show in vitro antibody depen-
dent enhancement (ADE) properties, we infected human
K562 hematopoietic cells with DENV-1 in the presence
of increasing concentrations of the antibodies. We used
the K562 cell line because it expresses only the Fc
gamma RII (CD32) receptor and thus provides a simple
and well-characterized system for the study of ADE
[28]. DENV-1 was used since all three of the human
monoclonal antibodies bound well to E protein of this
serotype (Figures 1 and 2), and the 4.8A antibody was
highly neutralizing against DENV-1 (Figure 5).
The results, shown in Figure 6, indicate that the all
three HMAbs were able to enhance viral infection, but
they did so with different patterns. HMAbs 3.6D and
4.8A enhanced infection at relatively low concentrations
(0.04 g/ml) and the amount of enhancement rose with
increasing HMAb concentrations. Enhancement induced
by the non-neutralizing 3.6D HMAb reached a plateau
above 0.4 g/ml, while enhancement induced by the 4.8A
HMAb peaked and subsequently fell at higher concen-
trations, consistent with its observed neutralization
activity. The 2.3D HMAb only showed evidence of
enhancement at concentrations above 4 g/ml, consistent
with the lower affinity this HMAb has for the DENV-1
E protein (see below). Interestingly, we also observed
that the three HMAbs differed markedly in their ability
to enhance dengue infection in vitro\with the neutraliz-
ing HMAb 4.8A showing the greatest effect.
Quantitation of HMAb/E protein binding affinity
To confirm the HMAb specificity for DENV E proteins
and to quantitate the affinity of each antibody for the
different DENV strains, we used biolayer interferometry
to examine binding between the antibodies and purified,
Figure 1 Validation of the ConA ELISA.D E N VEp r o t e i nf r o m
serotypes 1-4 derived from DENV infected LLC-MK-2 cells was
immobilized by ConA. Reactivity with patient serum and dengue
negative human serum diluted in PBS/Tween as well as MMAbs 4G2
and 3H5 was measured by detection with HRP anti-human and anti-
mouse IgG, respectively. MMAb 4G2 were tested at 5 ug/ml. Mouse
MAb 3H5 was tested as undiluted culture fluid. Negative controls of
uninfected LLC-MK-2 culture fluid and Vaccinia ADA were also
tested.
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these experiments, the E proteins were chemically
coupled to biotin and conjugated to the surface of strep-
tavidin-coated fiber optic probes. The conjugated probes
were placed in solutions with different concentrations of
each antibody. Binding of the antibodies to the E pro-
teins on the surface of the probes was measured by the
change in interference from light reflected from the sur-
face of the probe. After binding, the probes were placed
in a solution without any antibody to similarly measure
the antibody/E protein dissociation. Kinetics of on (Fig-
ure 7A) and off (Figure 7B) rates and equilibrium disso-
ciation constants (Figure 7C) were calculated assuming
a 1:1 binding ratio using the manufacturer’ss o f t w a r e
(Figure 7). As expected from the patient serum neutrali-
zation results and the HMAb ELISA results, all three of
the antibodies bound to DENV-1 as well as DENV-2 E
protein. HMAb 2.3D showed the weakest binding, with
dissociation constants of 2 × 10
-8 M for DENV-2 and 6
×1 0
-7 M for DENV-1. The affinity of HMAb 3.6D was
Figure 2 Serial five fold dilutions of each HMAb. Starting at 10,000 ng/ml, Human and Mouse MAbs were tested by ConA ELISA against each
dengue virus serotype. A HMAb 2.3D. B 3.6D. C 4.8A. D. 4G2 (dilutions were started at 50,000 ng/ml). E. 3H5 (tested as dilutions of culture fluid).
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-9
M for DENV-1 E and 5 × 10
-9 M for DENV-2 E protein.
The increased affinities seen with the 3.6D antibody
were due to both increased binding (on rate) kinetics, as
well as decreased dissociation (off rate) kinetics. The
low binding activities of 2.3D and 3.6D against DENV-3
or -4 E proteins precluded measurement of affinities of
these antibodies. HMAb 4.8A showed high affinity bind-
ing to all four DENV E proteins with dissociation con-
stants in the 2-5 × 10
-9 M range. Binding was slightly
better with the DENV-1 and -2 E proteins (2 × 10
-9 M)
than with the DENV-3 and -4 E proteins (3-5 × 10
-9 M).
The broad binding reactivity of MAb 4.8A against the
4 serotypes of DENV contrasts sharply with the DENV-
1 and -3 specificity observed in the neutralization assays
with this antibody. The ConA ELISA and biolayer inter-
ferometry binding assays do not reproduce the subtleties
of binding to the surface of an assembled virion. While
the purified E proteins are apparently correctly glycosy-
lated, they are truncated at the pre-anchor domain.
Therefore, they are not interacting with a lipid mem-
brane and do not form complexes with neighboring E
subunits as on the surface of an infectious virion. While
4.8A exhibits potent neutralizing activity against DENV-
1 and -3, its target epitope may be sufficiently shielded
or altered on DENV-2 and -4 viral particle E proteins to
lower this neutralization activity.
Discussion
In this study we have demonstrated that it is feasible to
derive human B cell lines producing HMAbs specific for
dengue virus E proteins. The three IgG HMAbs
reported here were produced by EBV transformation of
circulating memory B cells obtained from a patient who
had dengue fever at least two years before. One HMAb,
4.8A, was broadly cross-reactive by ELISA with all four
dengue serotypes. HMAb 2.3D bound to DENV-1, 2, 3
by ELISA, while 3.6D reacted with only DENV-1 and 2
E proteins by ELISA. Cross-competition binding assays
performed with DENV-1 E proteins indicate that the
three HMAbs recognize distinct sites. Of the three
HMAbs only 4.8A showed potent neutralizing activity
against DENV-1 and DENV-3 and little or no inhibitory
activity against DENV 2 and 4. The neutralizing activity
Figure 3 Cross-competition between HMAbs. A cross-
competition assay was performed to determine whether the three
HMAbs and MMAb 4G2 recognized overlapping or non-overlapping
sties on DENV-1 E protein. Purified MMAb 4G2 and HMAbs were
incubated with biotinylated HMAbs, washed, and the presence of
biotinylated antibodies was detected using streptavidin.
Figure 4 Virus neutralization by patient serum. Approximately 100 FFU of virus were incubated with serial dilutions of heat inactivated
patient serum and then allowed to infect LLC-MK-2 cells. Following an incubation period, virus foci were detected using specific mouse anti-
DENV E protein MMAb E60.
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serum. It is not clear why 4.8A showed lower neutraliza-
tion activity against DENV-2 and 4 even though it
reacted well to these serotypes in ELISA and biolayer
interferometry assays using disrupted or monomeric E
protein. Very likely there are subtle differences of epi-
tope exposure on viral particles in the different sero-
types. Neither of the two other HMAbs, 2.3D and 3.6D,
was able to neutralize DENV.
All three HMAbs demonstrated concentration depen-
dent enhancement of infection when antibody was
incubated with virus prior to infecting Fc receptor-bear-
ing cells. Antibody Dependent Enhancement (ADE) was
first proposed by Hawkes in 1964 who theorized that
pre-existing antibody, either neutralizing but at sub-neu-
tralizing concentrations or non-neutralizing, binds to the
viral particle and enhances the efficiency of viral uptake
into the target cell [29]. Halstead described this in vitro
phenomenon in DENV in 1970 [4]. Antibody dependent
enhancement characteristics have been found with both
neutralizing and non-neutralizing anti-DENV MMAbs
[5]. The non-neutralizing anti-E protein Ab described by
Figure 5 Virus neutralization by HMAbs. Approximately 100 FFU of virus were incubated with serial dilutions of purified monoclonal antibody.
Virus mixtures were allowed to infect LLC-MK-2 cells and then incubated at 37C. Virus foci were detected using anti-DENV E protein MMAb E60.
Results are expressed as pooled data from two independent experiments with three replicates each. A HMAb 2.3D. B 3.6D. C 4.8A. D 4G2. E 3H5.
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enhancement and antibody concentration similar to that
seen with HMAbs 2.3D and 3.6D. Our neutralizing
HMAb 4.8A also showed a drop in enhancement activ-
ity at higher concentrations, consistent with its pre-
sumed ability to block viral entry at full Ab occupancy.
Enhancement of infection by HMAbs correlates well
with affinity. 3.6D and 4.8A bind tightly to DENV-1 E
(Kd =1 0
-9 M) and they enhance at low concentrations,
while 2.3D, which binds less tightly (Kd =1 0
-7 M),
enhances only at higher concentrations. We also noted
that our three HMAbs showed different levels of
enhancement that were not explained by affinity. Cur-
iously, the only neutralizing HMAb, 4.8A, showed the
greatest enhancement. Although HMAb 4.8A appears to
neutralize and enhance in the same range of concentra-
tions (see Figures 5C and 6), each characteristic was
measured in vitro using a different assay system with
different concentrations of virus. We do not know if
this will be a consistent phenomenon associated with
neutralizing HMAbs. In addition, the relationship
between ADE and neutralizing versus non-neutralizing
antibodies needs to be more fully explored in cells with
different types of Fc receptors.
Current information on mapping of neutralization epi-
topes of dengue viruses is based almost entirely on stu-
dies with MMAbs that were generated by short-term
immunization of mice with infectious virus particles or
with purified viral proteins [10,14]. A major drawback
to studies with murine antibodies is that dengue virus
infection does not occur naturally in mice and signifi-
cant disease is usually only achieved through intracereb-
ral inoculation or the use of genetically modified mice
with immune deficits. The mouse is not a model for
DHF or DSS. Human and mouse antibody repertoires
are also distinctly different [30]. The variable regions of
the heavy chain (VH) and lambda light chains (V) have a
significantly greater number of combinations in humans
than in mice. The germ line complexity of the DH and
JH loci is also greater in humans and the greater length
of the CDR-H3 region of the heavy chain allows for
more complex binding surfaces. Length and amino acid
utilization is very different in this region in humans
compared to mice. In humans, this region is able to
form grooves, cavities and knobs, increasing the poten-
tial range of epitope recognition [31,32].
In addition, humans and mice differ in their major
histocompatability complex class II and I gene regions
and therefore will present similar antigens differently.
Accordingly, human and mouse repertoires may be
more, or less, likely to target certain epitopes or they
may target similar epitopes but recognize different con-
formations on them [33,34]. We have incomplete knowl-
edge of how mouse and human antibody responses to
dengue viruses differ. However if antibody plays any role
in the pathogenesis of DHF/DSS, it is obviously impor-
tant to focus studies of antibody responses in the host
species in which DHF/DSS occurs.
Figure 6 Enhanced DENV uptake by K562 cells in the presence of HMAbs. Human K562 cells were infected with DENV-1 in the presence of
increasing concentrations of the antibodies. RNA was extracted from cell lysates and quantitative RT-PCR was performed with a DENV-1 specific
primer pair specific for the NS1 region as a measure of infectious equivalents. A HMAb 2.3D. B 3.6D. C 4.8A.
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HMAbs specific for DENV E proteins can be generated
by EBV transformation of B cells from patients at least
two years after naturally acquired dengue infections. We
have generated three such antibodies that recognize
three distinct antigenic sites, exhibit varying degrees of
serotypic cross-reactive, and show differences in neutra-
lizing, non-neutralizing and enhancing activity. Our
results show that it will be possible to generate libraries
of HMAbs that will allow a more complete understand-
ing of the role antibodies play in protection and patho-
genesis of DENV infections.
Acknowledgements
The authors would like to thank Tom F. Everts, Marielys Figueroa-Sierra, Greg
Hogancamp and Craig R. Rees for technical assistance.
Funding was provided by DoD awards N00173-06-1-G901 and N00173-07-1-
G015 to SI and SFM, the South Louisiana Institute for Infectious Disease
Research Fellowship Grant to JSS, and Tulane Research Enhancement Grant
to JER.
Author details
1Section of Pediatric Infectious Disease, Department of Pediatrics, Tulane
University School of Medicine, New Orleans, LA, USA.
2Department of
Biological Sciences, Florida Gulf Coast University, Fort Myers, FL, USA.
3Department of Microbiology, University of Washington School of Medicine,
Seattle, WA, USA.
Authors’ contributions
JSS participated in the study design and coordination, performed the EBV
transformation, the HMAb purification, and ELISA titrations, analyzed the
data and drafted the manuscript. JMC participated in the study design and
coordination, performed the neutralization assays, analyzed the data and
drafted the manuscript. CON performed the enhancement assays and
helped perform the neutralization assays. NMO performed the biotinylation
of HMAbs and competition assays. KAF performed the biolayer interference
affinity experiments. SI, SFM, and JER conceived and designed the project,
coordinated the study, analyzed the data, and helped draft the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 October 2009
Accepted: 4 February 2010 Published: 4 February 2010
References
1. Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S,
Ennis FA, et al: Antibody-dependent cellular cytotoxicity mediated by
plasma obtained before secondary dengue virus infections: potential
involvement in early control of viral replication. J Infect Dis 2007,
195(8):1108-16.
2. Sabin AB: Research on dengue during World War II. Am J Trop Med Hyg
1952, 1(1):30-50.
3. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S,
Salitul V, et al: Risk factors in dengue shock syndrome: a prospective
epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J
Epidemiol 1984, 120(5):653-69.
4. Halstead SB: Observations related to pathogensis of dengue hemorrhagic
fever. VI. Hypotheses and discussion. Yale J Biol Med 1970, 42(5):350-62.
5. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, et al: The dual-
specific binding of dengue virus and target cells for the antibody-
dependent enhancement of dengue virus infection. J Immunol 2006,
176(5):2825-32.
6. Chaturvedi UC, Shrivastava R, Nagar R: Dengue vaccines: problems and
prospects. Indian J Med Res 2005, 121(5):639-52.
Figure 7 HMAb measured by biolayer interferometry. Label free,
real time binding analysis between the HMAbs 2.3D, 3.6D and 4.8A
and purified, recombinant E protein from each DENV serotype to
measure binding affinity was performed. The affinities of 2.3D and
3.6D for DENV 3 or 4 E proteins could not be measured due to Ab
aggregation at the higher concentrations needed to detect lower
affinity binding. A: Association rate constants (kon) for Ab:E protein
interactions. B: Dissociation rate constants (koff) for Ab:E protein
interactions. C: Equilibrium dissociation constants (Kd) for HMAb:E
protein complexes.
Schieffelin et al. Virology Journal 2010, 7:28
http://www.virologyj.com/content/7/1/28
Page 10 of 117. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC: The envelope
glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature
1995, 375(6529):291-8.
8. Modis Y, Ogata S, Clements D, Harrison SC: A ligand-binding pocket in the
dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003,
100(12):6986-91, PMCID: 165817..
9. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S,
et al: Antibody recognition and neutralization determinants on domains
I and II of West Nile Virus envelope protein. J Virol 2006, 80(24):12149-59.
10. Crill WD, Roehrig JT: Monoclonal antibodies that bind to domain III of
dengue virus E glycoprotein are the most efficient blockers of virus
adsorption to Vero cells. J Virol 2001, 75(16):7769-73.
11. Roehrig JT, Bolin RA, Kelly RG: Monoclonal antibody mapping of the
envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998,
246(2):317-28.
12. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE,
Schlesinger JJ, et al: Type- and subcomplex-specific neutralizing
antibodies against domain III of dengue virus type 2 envelope protein
recognize adjacent epitopes. J Virol 2007, 81(23):12816-26.
13. Gromowski GD, Barrett ND, Barrett AD: Characterization of dengue virus
complex-specific neutralizing epitopes on envelope protein domain III of
dengue 2 virus. J Virol 2008, 82(17):8828-37.
14. Halstead SB: Neutralization and antibody-dependent enhancement of
dengue viruses. Adv Virus Res 2003, 60:421-67.
15. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE: Characterization
of CD4-induced epitopes on the HIV type 1 gp120 envelope
glycoprotein recognized by neutralizing human monoclonal antibodies.
AIDS Res Hum Retroviruses 2002, 18(16):1207-17.
16. Robinson JE, Holton D, Liu J, McMurdo H, Murciano A, Gohd R: A novel
enzyme-linked immunosorbent assay (ELISA) for the detection of
antibodies to HIV-1 envelope glycoproteins based on immobilization of
viral glycoproteins in microtiter wells coated with concanavalin A. J
Immunol Methods 1990, 132(1):63-71.
17. Robinson JE, Holton D, Pacheco-Morell S, Liu J, McMurdo H: Identification
of conserved and variant epitopes of human immunodeficiency virus
type 1 (HIV-1) gp120 by human monoclonal antibodies produced by
EBV-transformed cell lines. AIDS Res Hum Retroviruses 1990, 6(5):567-79.
18. Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE: Epitopic
analysis of antigenic determinants on the surface of dengue-2 virions
using monoclonal antibodies. Am J Trop Med Hyg 1985, 34(1):162-9.
19. Ivy JEN, Clements D: Inventor U.S. patent 6,165,477. 2000.
20. Cuzzubbo AJ, Endy TP, Nisalak A, Kalayanarooj S, Vaughn DW, Ogata SA,
et al: Use of recombinant envelope proteins for serological diagnosis of
Dengue virus infection in an immunochromatographic assay. Clin Diagn
Lab Immunol 2001, 8(6):1150-5.
21. Cole KS, Alvarez M, Elliott DH, Lam H, Martin E, Chau T, et al:
Characterization of neutralization epitopes of simian immunodeficiency
virus (SIV) recognized by rhesus monoclonal antibodies derived from
monkeys infected with an attenuated SIV strain. Virology 2001,
290(1):59-73.
22. Robinson JE, Cole KS, Elliott DH, Lam H, Amedee AM, Means R, et al:
Production and characterization of SIV envelope-specific rhesus
monoclonal antibodies from a macaque asymptomatically infected with
a live SIV vaccine. AIDS Res Hum Retroviruses 1998, 14(14):1253-62.
23. Morita K, Tanaka M, Igarashi A: Rapid identification of dengue virus
serotypes by using polymerase chain reaction. J Clin Microbiol 1991,
29(10):2107-10.
24. Thu HM, Lowry K, Myint TT, Shwe TN, Han AM, Khin KK, et al: Myanmar
dengue outbreak associated with displacement of serotypes 2, 3, and 4
by dengue 1. Emerg Infect Dis 2004, 10(4):593-7.
25. Morens DM, Venkateshan CN, Halstead SB: Dengue 4 virus monoclonal
antibodies identify epitopes that mediate immune infection
enhancement of dengue 2 viruses. J Gen Virol 1987, 68(Pt 1):91-8.
26. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS: Antibody-dependent
enhancement of dengue virus growth in human monocytes as a risk
factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989,
40(4):444-51.
27. Morens DM, Halstead SB: Measurement of antibody-dependent infection
enhancement of four dengue virus serotypes by monoclonal and
polyclonal antibodies. J Gen Virol 1990, 71(Pt 12):2909-14.
28. Looney RJ, Ryan DH, Takahashi K, Fleit HB, Cohen HJ, Abraham GN, et al:
Identification of a second class of IgG Fc receptors on human
neutrophils. A 40 kilodalton molecule also found on eosinophils. JE x p
Med 1986, 163(4):826-36.
29. Hawkes RA: Enhancement of the Infectivity of Arboviruses by Specific
Antisera Produced in Domestic Fowls. Aust J Exp Biol Med Sci 1964,
42:465-82.
30. Schroeder HW Jr: Similarity and divergence in the development and
expression of the mouse and human antibody repertoires. Dev Comp
Immunol 2006, 30(1-2):119-35.
31. Johnson G, Wu TT: Preferred CDRH3 lengths for antibodies with defined
specificities. Int Immunol 1998, 10(12):1801-5.
32. Collis AV, Brouwer AP, Martin AC: Analysis of the antigen combining site:
correlations between length and sequence composition of the
hypervariable loops and the nature of the antigen. J Mol Biol 2003,
325(2):337-54.
33. Kumanovics A, Takada T, Lindahl KF: Genomic organization of the
mammalian MHC. Annu Rev Immunol 2003, 21:629-57.
34. Yeager M, Kumar S, Hughes AL: Sequence convergence in the peptide-
binding region of primate and rodent MHC class Ib molecules. Mol Biol
Evol 1997, 14(10):1035-41.
doi:10.1186/1743-422X-7-28
Cite this article as: Schieffelin et al.: Neutralizing and non-neutralizing
monoclonal antibodies against dengue virus E protein derived from a
naturally infected patient. Virology Journal 2010 7:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schieffelin et al. Virology Journal 2010, 7:28
http://www.virologyj.com/content/7/1/28
Page 11 of 11